Philogen. Philogen is a biotechnology company with a mission to innovate the treatment of cancer and other serious conditions
Never miss Philogen.com updates: Start reading the news feed of Philogen right away! Unfortunately, we cannot detect RSS feed on this website, but you may observe related news or Philogen.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.
News, stories and media buzz related to Philogen
-
Cover Story: Global Biotech Reportvia
businessfacilities
By Stefanie Ramsperger From the March/April 2016 Issue The life sciences industry has fared reasonably well in past economic recessions, but today it must weather a volatile marketplace-characterized by economic uncertainty, reform-driven pricing pressures...
-
South Bulletin 96, 30 November 2016via
southcentre
Big support for UN Access to Medicines High Level Panel’s Report There is an urgent need not only to support but to undertake follow up activities relating to the recently released report of the UN Secretary General’s high level panel on access to medicines...
-
Merck KGaA, Darmstadt, Germany to Present Data at ASCO That Illustrate How the Company is Tackling Difficult-to-Treat Ca...via
military-technologies
ROCKLAND, Massachusetts, May 15, 2015 /PRNewswire/ -- ASCO Abstract # Avelumab*: 3023, 3044, 3055, TPS9386, TPS3101, 4042, 4047, 5509, 8034; evofosfamide: TPS9089, 8579; tepotinib: 2591; tecemotide[†]: 3036. Merck KGaA, Darmstadt, Germany, will be...
-
Shire to Acquire Dyax for up to $6.5 Billionvia
spjnews
Shire plc (LSE: SHP, NASDAQ: SHPG) and Dyax Corp. (NASDAQ: DYAX) today announced that Shire will acquire Dyax for $37.30 in cash per Dyax share, for aggregate upfront consideration of approximately $5.9 billion. Dyax shareholders may receive additional...
-
Merck to Present Data at ASCO That Illustrate How the Compan replied by Helen.zhang @ Mon, 18 May 2015 17:25:49 +0800via
blogs.sgforums
DARMSTADT, Germany /PRNewswire/ -- - NOT INTENDED FOR US AND UK BASED MEDIA - ASCO Abstract # Avelumab*: 3023, 3044, 3055, TPS9086, TPS3101, 4042, 4047, 5509, 8034; evofosfamide: TPS9089, 8579; tepotinib: 2591; tecemotide[†]: 3036. New data on priority...
You may also like
Managing Myeloma is an educational initiative dedicated to developing tools, information, and resources that support improved ther...
SOCRATES Journal is an international, refereed, and indexed scholarly publication focused on public policy, administration, and ph...
Proximity Switches Manufacturer,Vibrator Controller...
SAI TECH CONTROLS is a famous Manufacturer,Supplier and Wholesaler of Proximity Switches,Vibrator controller and SMPS Power Suppli...
Philogen.com popular pages
-
Philogen is a Swiss-Italian biotechnology company
Philogen is a biotechnology company with a mission to innovate the treatment of cancer and other serious conditions
-
Philogen - innovating targeting
Philogen - innovating targeting
-
DEKAVIL - Philogen - innovating targeting
Dekavil is an immunocytokine consisting of a targeting antibody fused to the anti-inflammatory cytokine interleukin-10 (IL10). Dekavil...
Some worthy website to observe next
Website parameters
-
20 years
Domain age
-
N/A
Visit duration
-
N/A
Daily visitors
-
N/A
Bounce rate
